绿十字

GC Biopharma, formerly known as Green Cross Corporation, is a leading South Korean biopharmaceutical company specializing in plasma-derived medicines, vaccines, and recombinant proteins. Founded in 1967, the company has established a global presence as a specialist in immunology, hematology, and rare diseases. Its flagship products include Alyglo (IVIG-SN 10%), which received FDA approval in 2023, and Hunterase, a treatment for Hunter syndrome marketed in over 10 countries. GC Biopharma operates extensive manufacturing facilities in South Korea and has historically maintained a strong presence in China through its subsidiary, Green Cross China. The company is committed to innovation in biologics and is actively expanding its global footprint through strategic partnerships and R&D investments. In 2024, the company underwent a significant strategic shift by divesting its Chinese operations to China Resources Boya Bio-pharmaceutical to focus on its core global growth initiatives.